JPH07270417A - Reagent for immunoassay and production thereof - Google Patents

Reagent for immunoassay and production thereof

Info

Publication number
JPH07270417A
JPH07270417A JP6127694A JP6127694A JPH07270417A JP H07270417 A JPH07270417 A JP H07270417A JP 6127694 A JP6127694 A JP 6127694A JP 6127694 A JP6127694 A JP 6127694A JP H07270417 A JPH07270417 A JP H07270417A
Authority
JP
Japan
Prior art keywords
water
antigen
antibody
carrier
latex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP6127694A
Other languages
Japanese (ja)
Other versions
JP3444649B2 (en
Inventor
Yoshie Matsumoto
美枝 松本
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sekisui Chemical Co Ltd
Original Assignee
Sekisui Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sekisui Chemical Co Ltd filed Critical Sekisui Chemical Co Ltd
Priority to JP06127694A priority Critical patent/JP3444649B2/en
Publication of JPH07270417A publication Critical patent/JPH07270417A/en
Application granted granted Critical
Publication of JP3444649B2 publication Critical patent/JP3444649B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Landscapes

  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)

Abstract

PURPOSE:To produce a highly sensitive reagent having excellent preservability and upon which natural coagulation or nonspecific coagulation does not occur by introducing a water-soluble polymer into and fixing it in a water-insoluble carrier, locally heightening the hydrophobic property of the carrier, increasing the adsorption quantity of an antibody or an antigen, and providing the carrier with hydrophilic property. CONSTITUTION:The reagent is produced by carrying an antibody or an antigen on a water-insoluble carrier and then adding an aqueous solution containing a water-soluble polymer having saccharose as a side chain in concentration range 0.01-4 pts. by wt. per 1 pt. by wt. of the carrier to an aqueous solution containing the antibody or the antigen. Latex particles are a desirable example for the water-insoluble carrier. The water-soluble polymer having saccharose is an ampholytic substance having a hydrophilic group and a hydrophobic group in one molecule and is made to have 20000-750000 molecular weight, preferably 350000-500000 molecular weight. Glycoside polymer e.g. homopolymer of glcosylethyl methacrylate is a desirable example for the polymer compound having saccharose as a side chain. The substance for the antibody or the antigen is protein, lipide, peptide, or their compounded bodies.

Description

【発明の詳細な説明】Detailed Description of the Invention

【0001】[0001]

【産業上の利用分野】本発明は抗原抗体反応を利用する
免疫測定用試薬に関し、より詳細には、高感度で非特異
反応が少ない免疫測定用試薬およびその製造方法に関す
る。
BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to an immunoassay reagent utilizing an antigen-antibody reaction, and more particularly to an immunoassay reagent having high sensitivity and less nonspecific reaction, and a method for producing the same.

【0002】[0002]

【従来の技術】生体成分から特定の物質を検出もしくは
定量する方法として抗原抗体反応が利用されている。抗
原抗体反応は、特異性が高く検出感度が高いため、臨床
検査の重要な手段として現在広く用いられている。抗原
抗体反応を利用する測定方法として、水溶液中で抗原抗
体反応を行わせる方法には、酵素免疫測定法(EI
A)、放射免疫測定法(RIA)、免疫比濁法(TI
A)などが知られている。
2. Description of the Related Art Antigen-antibody reaction is used as a method for detecting or quantifying a specific substance from a biological component. Since the antigen-antibody reaction has high specificity and high detection sensitivity, it is currently widely used as an important means for clinical tests. As a measurement method utilizing the antigen-antibody reaction, a method of performing the antigen-antibody reaction in an aqueous solution includes an enzyme immunoassay (EI
A), radioimmunoassay (RIA), immunoturbidimetric assay (TI)
A) and the like are known.

【0003】中でもラテックス粒子やプラスチックプレ
ートを水不溶性担体として使用する場合、抗原もしくは
抗体である被測定物質に対する抗体もしくは抗原を上記
のような水不溶性担体に効率的に、かつ安定性良く固定
化させることは、高感度かつ安定性の高い診断薬を製造
する上で、重要な技術である。
In particular, when latex particles or a plastic plate is used as the water-insoluble carrier, the antibody against the substance to be measured which is the antigen or the antibody or the antigen is efficiently and stably immobilized on the water-insoluble carrier as described above. This is an important technique for producing a highly sensitive and highly stable diagnostic drug.

【0004】不溶性担体に抗原あるいは抗体を固定する
方法としては、吸着あるいは共有結合などの方法がある
が、一般には吸着が簡単であり、かつ抗原活性あるいは
抗体活性を損なうことがないので繁用されている。不溶
性担体への抗原あるいは抗体の吸着効率を高める手段と
しては、使用する抗原あるいは抗体の量を増やす以外に
以下のような方法が考えられていた。
As a method of immobilizing an antigen or an antibody on an insoluble carrier, there are methods such as adsorption or covalent bond, but generally, adsorption is easy and it is widely used because it does not impair the antigen activity or the antibody activity. ing. In addition to increasing the amount of the antigen or antibody used, the following methods have been considered as means for increasing the efficiency of adsorption of the antigen or antibody on the insoluble carrier.

【0005】(1) 粒径の大きいラテックス粒子を用い、
抗原または抗体の担体との接触面積を大きくする(特開
平5−297002)。
(1) Using latex particles having a large particle size,
The contact area of the antigen or antibody with the carrier is increased (JP-A-5-297002).

【0006】(2) 表面が多孔性または粗さに富む担体を
用い、抗原または抗体の接触面積を大きくする(特公平
3−22944、特開平4−174360)。
(2) A carrier having a porous surface or a high roughness is used to increase the contact area of an antigen or an antibody (Japanese Patent Publication No. 3-22944, JP-A-4-174360).

【0007】このほか、物理吸着には吸着させる抗原あ
るいは抗体と、水不溶性担体の間の疎水性相互作用が大
きな役割を果たしていることから、表面の疎水性が高い
ポリスチレン系のラテックス粒子を用いることも有効で
ある。ポリスチレンラテックス系のラテックス粒子は、
合成物質であるため、保存時の安定性が他の担体よりも
優れ、抗原、抗体などの蛋白質や脂質などの生理活性物
質を強く吸着し、さらにこうして結合した抗原および抗
体の性質を変化なく保持しうる点でも優れているため多
くの免疫反応試薬に用いられ、特に凝集反応試薬の担体
として繁用されている。
[0007] In addition, since the hydrophobic interaction between the adsorbed antigen or antibody and the water-insoluble carrier plays a large role in physical adsorption, use of polystyrene latex particles having high surface hydrophobicity. Is also effective. Polystyrene latex-based latex particles are
Being a synthetic substance, it has better storage stability than other carriers, strongly adsorbs proteins such as antigens and antibodies and physiologically active substances such as lipids, and retains the properties of the bound antigens and antibodies unchanged. Since it is also excellent in that it can be used, it is used in many immunoreaction reagents, and is particularly often used as a carrier for agglutination reagents.

【0008】しかしながら、ポリスチレンラテックス系
の合成ラテックスでは、その保存中にラテックス粒子が
自然凝集を起こしたり、目的物質以外の物質同士の反応
による、いわゆる非特異凝集を生じる嫌いがある。この
問題を防止するために、従来、感作したラテックス粒子
の懸濁液にウシ血清アルブミン、ウマ血清アルブミンな
どの免疫学的に不活性なアルブミン類を添加して、ラテ
ックス粒子の疎水性表面を覆い、表面荷電を負に維持す
ることにより、ラテックス粒子の自然凝集を防止し、妨
害物質による非特異凝集を防止した免疫学的反応用ラテ
ックス試薬が提案された(公開昭58−144748、
公開平3−94161)。
However, in the polystyrene latex synthetic latex, there is a tendency that the latex particles spontaneously aggregate during storage, or so-called non-specific aggregation occurs due to reaction between substances other than the target substance. In order to prevent this problem, conventionally, immunologically inactive albumins such as bovine serum albumin and equine serum albumin were added to the sensitized latex particle suspension to remove the hydrophobic surface of the latex particles. A latex reagent for immunological reaction was proposed in which natural aggregation of latex particles was prevented and nonspecific aggregation due to interfering substances was prevented by covering and keeping the surface charge negative (JP-A-58-144748).
Kohei 3-94161).

【0009】[0009]

【発明が解決しようとする課題】しかし、表面の疎水性
が高く、かつ上記特開平5−297002、特公平3−
22944および特開平4−174360の粒子のよう
に、吸着表面積が大きいだけでは、目的とする抗原もし
くは抗体以外の蛋白質までも非特異的に吸着してしま
い、それに続いて非特異反応や非特異凝集も引き起こす
恐れがあった。
However, the hydrophobicity of the surface is high, and the above-mentioned JP-A-5-297002 and JP-B-3-
As in the particles of No. 22944 and JP-A-4-174360, if the adsorption surface area is large, even proteins other than the target antigen or antibody will be nonspecifically adsorbed, followed by nonspecific reaction and nonspecific aggregation. Could also cause

【0010】また、ポリスチレンラテックス系の合成ラ
テックスでは、上記のような不活性アルブミンの添加に
よっても長時間の保存においては感作担体の自然凝集あ
るいは非特異凝集を阻止することは不可能であった。ま
た、使用するアルブミンの濃度がかなり高いため粒子表
面の負荷電が大きくなりすぎて、粒子が安定化し、本来
必要な抗原抗体反応までも抑制してしまうことがあっ
た。
In addition, in the case of a polystyrene latex-based synthetic latex, it was impossible to prevent spontaneous aggregation or non-specific aggregation of the sensitized carrier even after long-term storage even by adding the above-mentioned inert albumin. . In addition, since the concentration of albumin used is considerably high, the negative charge on the surface of the particles becomes too large, and the particles are stabilized, sometimes suppressing the originally necessary antigen-antibody reaction.

【0011】本発明の目的は、上記の点に鑑み、自然凝
集あるいは非特異凝集を発生する恐れがなく、長時間保
存しうる、高感度を示す、免疫測定用試薬を提供するこ
とにある。
In view of the above points, an object of the present invention is to provide an immunoassay reagent which has high sensitivity and can be stored for a long time without the risk of spontaneous aggregation or non-specific aggregation.

【0012】[0012]

【課題を解決するための手段】本発明者は、上記目的を
達成すべく鋭意研究を行った結果、特定の水溶性高分子
を水不溶性担体の表面に固定化することにより、高感度
で非特異反応が少ない免疫測定用試薬が得られることを
見出だし、本発明を完成した。
Means for Solving the Problems As a result of intensive studies aimed at achieving the above-mentioned object, the present inventor has found that a specific water-soluble polymer is immobilized on the surface of a water-insoluble carrier, thereby providing high sensitivity and non-sensitivity. The inventors have found that an immunoassay reagent with less specific reaction can be obtained, and completed the present invention.

【0013】すなわち、本発明により、抗体または抗原
を担持した水不溶性担体に、側鎖に糖類を有する水溶性
高分子が導入されてなる免疫測定用試薬が提供せられ
る。
That is, according to the present invention, there is provided an immunoassay reagent comprising a water-insoluble carrier carrying an antibody or an antigen, to which a water-soluble polymer having a saccharide in a side chain is introduced.

【0014】本発明による免疫測定用試薬は、水不溶性
担体に抗体または抗原を担持した後、同担体および抗体
または抗原を含む水性液に、側鎖に糖類を有する水溶性
高分子を担体1重量部に対し0.01〜4重量部になる
ような濃度で含む水性液を添加することにより製造され
る。
The immunoassay reagent according to the present invention comprises an antibody or an antigen supported on a water-insoluble carrier, and an aqueous liquid containing the carrier and the antibody or the antigen. It is produced by adding an aqueous liquid containing 0.01 to 4 parts by weight per part.

【0015】本発明による免疫測定用試薬は、また、水
不溶性担体に抗体または抗原を担持させる際に、担持前
または担持と同時に、担体を含む水性液に、側鎖に糖類
を有する水溶性高分子を担体1重量部に対し0.005
〜0.15重量部になるような濃度で含む水性液を添加
することによって製造される。
The immunoassay reagent according to the present invention also has a water-soluble high-solubility having a saccharide in a side chain in an aqueous solution containing the carrier before or simultaneously with the loading of the antibody or antigen on the water-insoluble carrier. 0.005 molecules per 1 part by weight of carrier
It is produced by adding an aqueous liquid containing a concentration of about 0.15 parts by weight.

【0016】本発明の好ましい実施態様において、免疫
測定用試薬は、免疫診断薬に用いる水不溶性担体に測定
対象物質である抗原または抗体に対応する抗体または抗
原を担持させたものである。
In a preferred embodiment of the present invention, the immunoassay reagent is a water-insoluble carrier used in an immunodiagnostic agent, which carries an antigen or an antibody corresponding to the antibody to be measured or an antigen.

【0017】水不溶性担体の好適な例はラテックス粒子
である。
A preferred example of a water-insoluble carrier is latex particles.

【0018】本発明に適用しうる水不溶性担体は、合成
によって得られるあらゆる種類のラテックス粒子のほ
か、ゼラチン粒子などでもよく、さらにはプラスチック
製のマイクロタイタープレートや、試験管であってもよ
い。また、その担体表面への感作については、物理吸着
方法のみならず、官能基を有する固体表面にも、既知の
方法である化学結合法や共有結合法により、効率的に感
作することができる。そのほか、動物の赤血球や、カオ
リン、炭素末なども本発明に適用できる。
The water-insoluble carrier applicable to the present invention may be any kind of latex particles obtained by synthesis, gelatin particles or the like, and may be a plastic microtiter plate or a test tube. Regarding the sensitization of the carrier surface, not only the physical adsorption method but also the solid surface having a functional group can be efficiently sensitized by the known chemical bonding method or covalent bonding method. it can. In addition, animal red blood cells, kaolin, carbon powder and the like can be applied to the present invention.

【0019】本発明で用いられる糖鎖を有する水溶性高
分子は、同一分子内に親水基と疎水基を共に有する、両
親媒性の物質であり、分子量2万〜75万、好ましくは
15万〜60万、最も好ましくは25万〜50万のもの
である。このような水溶性高分子としては、たとえば、
既知の方法によって合成されるグルコシルエチルメタク
リレートやガラクトシルエチルメタクリレートのホモポ
リマー(国際公開番号:WO90/04598)が例示
され、また、ポリエチレングリコールなどの合成高分子
や、動物の血清アルブミンなどを蛋白質分解酵素、酸、
その他の適当な手段で加水分解した分解生成物に、糖類
を適当な手段で結合させたものを適当な手段で精製した
ものなども使用できる。
The water-soluble polymer having a sugar chain used in the present invention is an amphipathic substance having both a hydrophilic group and a hydrophobic group in the same molecule, and has a molecular weight of 20,000 to 750,000, preferably 150,000. ˜600,000, most preferably 250,000 to 500,000. As such a water-soluble polymer, for example,
Examples include homopolymers of glucosylethyl methacrylate and galactosylethyl methacrylate (International Publication Number: WO90 / 04598) synthesized by a known method, and synthetic polymers such as polyethylene glycol and animal serum albumin are proteolytic enzymes. ,acid,
It is also possible to use a product obtained by binding a saccharide to a decomposition product hydrolyzed by other appropriate means by an appropriate means and purifying by a suitable means.

【0020】側鎖に糖類を有する水溶性高分子化合物の
好適な例は、グリコシルエチルメタクリレートのホモポ
リマーなどのグリコシド重合体である。
A preferred example of the water-soluble polymer compound having a saccharide in the side chain is a glycoside polymer such as a homopolymer of glycosyl ethyl methacrylate.

【0021】糖鎖を有する水溶性高分子の分子量は、7
5万より大きいと、従来技術について説明した、長期間
保存時のラテックス試薬の非特異凝集の問題が解決され
ず、2万より小さいと、ラテックス粒子表面の被覆およ
び親水性の付与に効果が十分得られない場合がある。
The water-soluble polymer having a sugar chain has a molecular weight of 7
If it is larger than 50,000, the problem of non-specific aggregation of the latex reagent during long-term storage explained in the prior art is not solved, and if it is smaller than 20,000, the effect is sufficient for coating the latex particle surface and imparting hydrophilicity. You may not get it.

【0022】水不溶性担体への抗体または抗原の担持の
後、同担体および抗体または抗原を含む水性液に、水溶
性高分子を含む水性液を添加することによって本発明に
よる免疫測定用試薬を製造される方法では、感作ラテッ
クス粒子などの水不溶性担体を任意の濃度で含みかつ担
体に担持した抗体または抗原を含む水性液に、水溶性高
分子を担体1重量部に対し0.01〜4重量部、好まし
くは0.05〜3.0重量部、最も好ましくは0.1〜
2.0重量部の濃度で含む水性液を添加する。
After carrying the antibody or antigen on the water-insoluble carrier, the reagent for immunoassay according to the present invention is produced by adding the aqueous liquid containing the water-soluble polymer to the aqueous liquid containing the carrier and the antibody or antigen. In the method described above, a water-soluble polymer is added to an aqueous liquid containing a water-insoluble carrier such as sensitized latex particles at an arbitrary concentration and containing an antibody or an antigen supported on the carrier in an amount of 0.01 to 4 per 1 part by weight of the carrier. Parts by weight, preferably 0.05 to 3.0 parts by weight, most preferably 0.1 to 3.0 parts by weight.
An aqueous liquor containing a concentration of 2.0 parts by weight is added.

【0023】この濃度が0.01重量部より少ないと、
表面の被覆によるラテックス試薬の安定性が充分でな
く、4.0重量部より多いと分散性が高すぎて測定感度
が低くなるので、水溶性高分子の濃度は担体1重量部に
対し0.01〜4.0重量部である。
If this concentration is less than 0.01 parts by weight,
The stability of the latex reagent due to the coating on the surface is not sufficient, and if it is more than 4.0 parts by weight, the dispersibility is too high and the measurement sensitivity becomes low. Therefore, the concentration of the water-soluble polymer is 0. It is from 01 to 4.0 parts by weight.

【0024】また、水不溶性担体への抗体または抗原の
担持前または担持と同時に、担体を含む水性液に、水溶
性高分子を含む水性液を添加することによって本発明に
よる免疫測定用試薬を製造される方法では、感作ラテッ
クス粒子などの水不溶性担体を任意の濃度に水性液に懸
濁し、この担体を含む水性液に、水溶性高分子を担体1
重量部に対し0.005〜0.15重量部、好ましくは
0.008〜0.10重量部、最も好ましくは0.01
〜0.05重量部の濃度で含む水性液を添加する。
The immunoassay reagent according to the present invention is prepared by adding an aqueous solution containing a water-soluble polymer to an aqueous solution containing the carrier before or simultaneously with the loading of the antibody or antigen on the water-insoluble carrier. In the method described above, a water-insoluble carrier such as sensitized latex particles is suspended in an aqueous liquid at an arbitrary concentration, and the water-soluble polymer is added to the carrier 1 in the aqueous liquid containing the carrier.
0.005 to 0.15 part by weight, preferably 0.008 to 0.10 part by weight, and most preferably 0.01
Add an aqueous liquid containing at a concentration of ~ 0.05 parts by weight.

【0025】この濃度が0.005重量部より少ない
と、表面の被覆によるラテックス試薬の安定性が充分で
なく、0.15重量部より多いと分散性が高すぎて測定
感度が低くなるので、水溶性高分子の濃度は担体1重量
部に対し0.005〜0.15重量部である。
When the concentration is less than 0.005 parts by weight, the stability of the latex reagent due to the coating of the surface is not sufficient, and when it is more than 0.15 parts by weight, the dispersibility is too high and the measurement sensitivity becomes low. The concentration of the water-soluble polymer is 0.005 to 0.15 part by weight with respect to 1 part by weight of the carrier.

【0026】本発明に適用しうる上記のような水不溶性
担体に感作する生理活性物質としては、通常の抗原また
は抗体が例示される。該抗原または抗体である物質は、
例えば蛋白質、脂質、ペプチドあるいはそれらの複合体
である。本発明は、特にそれ自身では担体に感作された
場合に反応性を獲得しにくい物質、つまり脂質やペプチ
ドなど分子量の小さいハプテンを感作した試薬について
効力を発揮する。例えば、リン脂質の混合液を抗原成分
としてラテックス粒子に感作させた抗リン脂質抗体検出
用診断薬などである。
As the physiologically active substance which can be applied to the present invention and which is sensitized to the above water-insoluble carrier, a usual antigen or antibody is exemplified. The substance that is the antigen or antibody is
Examples are proteins, lipids, peptides or complexes thereof. The present invention is particularly effective for a substance which is difficult to acquire reactivity when sensitized to a carrier by itself, that is, a reagent sensitized with a hapten having a small molecular weight such as a lipid or a peptide. For example, it is a diagnostic agent for detecting antiphospholipid antibody in which latex particles are sensitized with a mixed solution of phospholipids as an antigen component.

【0027】不溶性担体に担持させる抗原の好適な例
は、リン脂質および/または脂質である。
Suitable examples of the antigen carried on the insoluble carrier are phospholipids and / or lipids.

【0028】本発明のラテックス試薬は、通常の緩衝液
に保存することができる。その成分としてはリン酸な
ど、既知のものが利用できる。また、緩衝液のpHおよ
びイオン強度は通常の生理学的な条件で使用できる。ま
た、非特異反応を抑制したり、抗原抗体反応を促進した
りする既知の物質も併用できる。
The latex reagent of the present invention can be stored in an ordinary buffer solution. Known components such as phosphoric acid can be used as the component. The pH and ionic strength of the buffer solution can be used under normal physiological conditions. In addition, known substances that suppress non-specific reactions or promote antigen-antibody reactions can also be used in combination.

【0029】また、本発明のラテックス試薬は懸濁液状
態で長時間安定に保存しうるが、凍結乾燥状態で保存す
ることもできる。その際、凍結乾燥時の安定剤として使
用されている一般的な薬剤との併用も可能である。
The latex reagent of the present invention can be stably stored in a suspension state for a long time, but can also be stored in a freeze-dried state. At that time, it is possible to use together with a general drug used as a stabilizer during freeze-drying.

【0030】ラテックス試薬の凝集度を検出する手段と
しては、目視で判定する方法、反応液の吸光度の変化を
装置により測定する方法などいずれでも利用できる。
As the means for detecting the agglutination degree of the latex reagent, any of a visual determination method, a method of measuring the change in the absorbance of the reaction solution with an apparatus, and the like can be used.

【0031】本発明による免疫測定用試薬は、抗リン脂
質抗体測定用のキットを構成することもできる。
The immunoassay reagent according to the present invention can also constitute a kit for assaying antiphospholipid antibodies.

【0032】[0032]

【作用】糖鎖を有する水溶性高分子を水不溶性担体に導
入することにより、水不溶性担体の疎水性を局所的に高
め、抗原または抗体の疎水性相互作用による吸着量を増
大させ、同時に水不溶性担体に親水性を付与することが
できる。これにより、非特異凝集の起こりにくい診断用
材料を提供することができる。
[Function] By introducing a water-soluble polymer having a sugar chain into a water-insoluble carrier, the hydrophobicity of the water-insoluble carrier is locally increased, and the adsorption amount by the hydrophobic interaction of the antigen or antibody is increased. Hydrophilicity can be imparted to the insoluble carrier. This makes it possible to provide a diagnostic material in which non-specific aggregation is unlikely to occur.

【0033】[0033]

【実施例】次に実施例により本発明をさらに詳しく説明
する。
EXAMPLES The present invention will be described in more detail with reference to examples.

【0034】実施例1 試薬および血清 (1) 10%(W/V)ポリスチレンラテックス液 ポリスチレンラテックス(積水化学社製、固型分10%
(W/V)、平均粒径0.400μm)をそのまま用い
た。
Example 1 Reagents and Serum (1) 10% (W / V) Polystyrene Latex Solution Polystyrene latex (Sekisui Chemical Co., Ltd., solid content 10%)
(W / V), average particle size 0.400 μm) were used as they were.

【0035】(2) 抗原液 カルジオライピンのエタノール溶液(シグマ社製、試薬
特級、5mg/ml)2mlと、フォスファチジルコリ
ン(ナカライテスク社製、試薬特級)をエタノール(ナ
カライテスク社製、試薬特級、99%)に溶解して10
mg/mlとしたもの10mlと、コレステロール(ナ
カライテスク社製、試薬特級)を同じく10mg/ml
のエタノール溶液にしたもの3mlとを合わせ、よく混
合し、抗原液とした。
(2) Antigen solution: 2 ml of an ethanol solution of cardiolipin (manufactured by Sigma, special grade reagent, 5 mg / ml) and phosphatidylcholine (special grade reagent manufactured by Nacalai Tesque, Inc., reagent grade special) , 99%) and 10
10 ml of 10 mg / ml and 10 mg / ml of cholesterol (special grade reagent manufactured by Nacalai Tesque)
3 ml of the ethanol solution prepared in 1 above was mixed well and used as the antigen solution.

【0036】(3) ブロッキング用緩衝液 100mM Na2 HPO4 (12水和物)および10
0mM Na2 HPO 4 (2水和物)を混合してpHを
7.40に調整したリン酸緩衝液(以下100mMリン
酸緩衝液と略す)に、グリコシルエチルメタクリレート
のホモポリマー(日本精化社製、平均分子量50万、Gl
ucosylethylmethacryrate :以下pGEMAと略す)を
1.0%(W/V)、アジ化ナトリウム(ナカライテス
ク社製、試薬特級)を0.1%(W/V)になるように
それぞれ溶解したものをブロッキング用緩衝液とした。
(3) Blocking buffer 100 mM Na2HPOFour(12 hydrate) and 10
0 mM Na2HPO Four(Dihydrate) is mixed to adjust the pH
Phosphate buffer adjusted to 7.40 (hereinafter 100 mM phosphorus
Glycosyl ethyl methacrylate in acid buffer)
Homopolymer (manufactured by Nippon Seika Co., average molecular weight 500,000, Gl
ucosylethylmethacryrate: hereinafter abbreviated as pGEMA)
1.0% (W / V), sodium azide (Nacalai Tes
KU Co., Ltd. special grade) to 0.1% (W / V)
Each dissolved product was used as a blocking buffer.

【0037】(4) ラテックス保存用緩衝液 100mMリン酸緩衝液にウシ血清アルブミン(Miles
社製、Fraction V、試薬特級、以下BSAと略す)を1
%(W/V)、アジ化ナトリウム(ナカライテスク社
製、試薬特級)を0.1%(W/V)、エチレンジアミ
ン四酢酸二ナトリウム二水和物(ナカライテスク社製、
試薬特級)を10mM、塩化コリン(ナカライテスク社
製、試薬特級)を500mMになるようにそれぞれ溶解
したものをラテックス保存用緩衝液とした。
(4) Latex storage buffer 100 mM phosphate buffer in bovine serum albumin (Miles
Company, Fraction V, special grade reagent, abbreviated as BSA below) 1
% (W / V), sodium azide (manufactured by Nacalai Tesque, special grade reagent) 0.1% (W / V), ethylenediaminetetraacetic acid disodium dihydrate (manufactured by Nacalai Tesque,
Reagent special grade) was dissolved in 10 mM, and choline chloride (Nacalai Tesque, Inc. special reagent grade) was dissolved to 500 mM to prepare a latex storage buffer solution.

【0038】(5) 検体希釈用緩衝液 100mMリン酸緩衝液にpGEMAを1.0%(W/
V)、BSAを0.25%(W/V)、アジ化ナトリウ
ムを0.1%(W/V)になるように溶解したものを検
体希釈用緩衝液とした。
(5) Specimen dilution buffer solution 1.0% (W /
V) and BSA dissolved in 0.25% (W / V) and sodium azide in 0.1% (W / V) were used as sample dilution buffers.

【0039】(6) 梅毒陰性血清 正常家兎より採取された血清であって、RPR−カード
テスト法(化学及び血清療法研究所社製)およびセロデ
ィアTRHAキット(富士レビオ社製)の両方により陰
性と判定されたものを用いた。
(6) Syphilis-negative serum Serum collected from normal rabbits, negative by both the RPR-card test method (Chemical and Serum Therapy Research Institute) and Cerrodia TRHA kit (Fujirebio) What was judged to be used.

【0040】(7) 梅毒陽性血清 実験的に梅毒菌を接種し、梅毒にした家兎より採取され
た血清であって、RPR−カードテスト法(化学及び血
清療法研究所社製)およびセロディアTRHAキット
(富士レビオ社製)の両方により陽性と判定されたもの
を用いた。
(7) Syphilis-positive serum Serum collected from rabbits experimentally inoculated with syphilis and syphilis, which are RPR-card test method (Chemical and Serum Therapy Research Institute) and Cerrodia TRHA The one determined to be positive by both kits (manufactured by Fujirebio) was used.

【0041】試薬の調製 10%(W/V)ポリスチレンラテックス液0.1ml
を8mlのポリカーボネートチューブ中で、長さ1cm
のスターラバーとともに、マグネチックスターラー上で
攪拌させながら、抗原液0.25mlを添加した。室温
で引き続き1時間攪拌したのち、ブロッキング用緩衝液
2.0ml(ラテックス粒子1重量部に対しpGEMA
2重量部)を添加し、引き続き1.5時間、室温で攪拌
した。その後、高速冷却遠心機(日立HR26型)で、
19000×g、10℃で30分遠心洗浄を行った。得
られたラテックスのペレットにラテックス保存用緩衝液
2.0mlを添加し、よく攪拌した。さらにラテックス
保存用緩衝液3.0mlを添加し、攪拌したのち、高速
冷却遠心機で、19000×g、10℃で30分遠心洗
浄を行った。この洗浄操作を3回繰り返した。
Preparation of reagents 0.1 ml of 10% (W / V) polystyrene latex solution
In a 8 ml polycarbonate tube, length 1 cm
0.25 ml of the antigen solution was added while stirring on a magnetic stirrer together with the star rubber of No. 1. After continuously stirring for 1 hour at room temperature, 2.0 ml of blocking buffer (1 part by weight of latex particles was added to pGEMA).
2 parts by weight) was added, and the mixture was subsequently stirred for 1.5 hours at room temperature. After that, with a high-speed cooling centrifuge (Hitachi HR26 type),
Centrifugal washing was performed at 19000 × g and 10 ° C. for 30 minutes. 2.0 ml of a buffer solution for latex storage was added to the obtained latex pellets, and they were stirred well. Further, 3.0 ml of a buffer solution for storing latex was added and stirred, and then centrifugal washing was performed with a high speed cooling centrifuge at 19000 × g and 10 ° C. for 30 minutes. This washing operation was repeated 3 times.

【0042】最終的に得られたペレットにラテックス保
存用緩衝液2.0mlを添加し、超音波破砕機(アスト
ラソン社製、マイクロチップ、出力目盛3、50%サイ
クル)にて氷浴中、1分間ソニケートし、分散させた。
こののち、さらにラテックス保存用緩衝液6.0mlを
添加し、十分混合させた。こうして、固型分0.125
%(W/V)のラテックス懸濁液を調製し、4℃にて保
存した。
To the finally obtained pellet, 2.0 ml of a buffer solution for latex storage was added, and the mixture was sonicated in an ice crusher (Microchip, output scale 3, 50% cycle, manufactured by Astrason) in an ice bath, Sonicate for 1 minute and disperse.
After this, 6.0 ml of a latex storage buffer was further added and mixed well. Thus, the solid content 0.125
% (W / V) latex suspension was prepared and stored at 4 ° C.

【0043】検体の調製 先に用意した家兎の梅毒陽性血清のうちRPR法で8倍
を示したものを、生理食塩水(0.9%NaCl水溶
液)にて、2、4、8、16倍希釈し、4、2、1、
0.5倍を示す陽性検体を調製した。また、陰性検体と
して生理食塩水および正常家兎の梅毒陰性血清をそのま
ま用いた。
Preparation of Specimens Among the syphilis-positive sera of rabbits prepared above, those showing 8 times by the RPR method were treated with physiological saline (0.9% NaCl aqueous solution) to give 2, 4, 8, 16 Dilute four times, 4, 2, 1,
A positive sample showing 0.5 times was prepared. In addition, physiological saline and syphilis-negative serum from normal rabbits were used as they were as negative samples.

【0044】自動分析装置による検体の測定 以下に、全自動生化学分析装置日立7150形(日立製
作所社製)により、検体中の抗リン脂質検体を測定する
方法を示す。
Measurement of Specimen by Automatic Analyzer The method for measuring an antiphospholipid specimen in a specimen by a fully automatic biochemical analyzer Hitachi Model 7150 (manufactured by Hitachi, Ltd.) is shown below.

【0045】 測定モード;Original Abs パラメータ;検体量 20μl ラテックス試薬量 50μl 検体希釈用緩衝液量 350μl 測定波長 ; 570nm 測定時間;検体分注後、ただちに検体希釈用緩衝液が添
加、混合され、そののち、ラテックス試薬が添加、混合
された。ラテックス試薬の添加後80秒後から320秒
後の吸光度の変化量を求め、これを反応量とした。
Measurement mode; Original Abs parameter; Specimen amount 20 μl Latex reagent amount 50 μl Specimen dilution buffer amount 350 μl Measurement wavelength; 570 nm measurement time; Specimen dilution buffer solution is added and mixed immediately after specimen dispensing, and then The latex reagent was added and mixed. The amount of change in the absorbance from 80 seconds to 320 seconds after the addition of the latex reagent was determined and used as the reaction amount.

【0046】検体;先に用意した梅毒陽性血清の希釈系
列および生理食塩水、梅毒陰性血清を検体としてそれぞ
れn=2で測定を行った。
Specimens: The syphilis-positive serum dilution series prepared above, physiological saline, and syphilis-negative sera were used as the specimens, and measurement was carried out at n = 2.

【0047】実施例2 実施例1において、ブロッキング用緩衝液中のpGEM
A濃度を0.5%(W/V)にした以外は実施例1と同
様の操作を行った(すなわち、ラテックス粒子1重量部
に対しpGEMAを1重量部添加した)。
Example 2 In Example 1, pGEM in blocking buffer
The same operation as in Example 1 was performed except that the A concentration was 0.5% (W / V) (that is, 1 part by weight of pGEMA was added to 1 part by weight of latex particles).

【0048】実施例3 実施例1において、ブロッキング用緩衝液中のpGEM
A濃度を0.1%(W/V)にした以外は実施例1と同
様の操作を行った(すなわち、ラテックス粒子1重量部
に対しpGEMAを0.2重量部添加した)。
Example 3 In Example 1, pGEM in blocking buffer
The same operation as in Example 1 was performed except that the A concentration was set to 0.1% (W / V) (that is, 0.2 part by weight of pGEMA was added to 1 part by weight of latex particles).

【0049】実施例4 実施例1において、ブロッキング用緩衝液中のpGEM
A濃度を0.05%(W/V)にした以外は実施例1と
同様の操作を行った(すなわち、ラテックス粒子1重量
部に対しpGEMAを0.1重量部添加した)。
Example 4 In Example 1, pGEM in blocking buffer was used.
The same operation as in Example 1 was performed except that the A concentration was 0.05% (W / V) (that is, 0.1 part by weight of pGEMA was added to 1 part by weight of latex particles).

【0050】比較例1 実施例1において、ブロッキング用緩衝液として、pG
EMAの代わりにBSAを1%(W/V)になるように
添加した緩衝液を用いた以外は実施例1と同様の操作を
行った(すなわち、ラテックス粒子1重量部に対しBS
Aを2重量部添加した)。
Comparative Example 1 In Example 1, pG was used as a blocking buffer.
The same operation as in Example 1 was carried out except that a buffer solution containing BSA at 1% (W / V) was used in place of EMA (that is, 1 part by weight of latex particles was used for BS.
2 parts by weight of A was added).

【0051】比較例2 実施例1において、ブロッキング用緩衝液中のpGEM
A濃度を0.001%(W/V)にした以外は実施例1
と同様の操作を行った(すなわち、ラテックス粒子1重
量部に対しpGEMAを0.002重量部添加した)。
Comparative Example 2 In Example 1, pGEM in blocking buffer was used.
Example 1 except that the A concentration was 0.001% (W / V)
The same operation was performed (that is, 0.002 parts by weight of pGEMA was added to 1 part by weight of latex particles).

【0052】比較例3 実施例1において、ブロッキング用緩衝液中のpGEM
A濃度を4.0%(W/V)にした以外は実施例1と同
様の操作を行った(すなわち、ラテックス粒子1重量部
に対しpGEMAを8重量部添加した)。
Comparative Example 3 In Example 1, pGEM in blocking buffer was used.
The same operation as in Example 1 was performed except that the A concentration was set to 4.0% (W / V) (that is, 8 parts by weight of pGEMA was added to 1 part by weight of latex particles).

【0053】測定結果1 実施例1〜4で得られた、各検体の吸収光度変化量を表
1に、および比較例1〜3で得られた、各検体の吸収光
度変化量を表1にそれぞれ示す(いずれもn=2の平均
値)。
Measurement Result 1 The amount of change in absorbed light intensity of each sample obtained in Examples 1 to 4 is shown in Table 1, and the amount of change in absorbed light intensity of each sample obtained in Comparative Examples 1 to 3 is shown in Table 1. Each is shown (in each case, an average value of n = 2).

【0054】[0054]

【表1】 [Table 1]

【表2】 これらの表から明らかなように、実施例の試薬は比較例
のものと比較して、陽性血清では高感度を示し、陰性血
清では非特異反応が全く見られないことがわかる。
[Table 2] As is clear from these tables, the reagents of Examples show higher sensitivity in positive sera and no non-specific reaction in negative sera, as compared with those in Comparative Examples.

【0055】実施例5 試薬および血清 (1) 10%(W/V)ポリスチレンラテックス液 ポリスチレンラテックス(積水化学社製、固型分10%
(W/V)、平均粒径0.400μm)をそのまま用い
た。
Example 5 Reagents and Serum (1) 10% (W / V) Polystyrene Latex Solution Polystyrene latex (Sekisui Chemical Co., Ltd., solid content 10%)
(W / V), average particle size 0.400 μm) were used as they were.

【0056】(2) 抗原液 カルジオライピンのエタノール溶液(シグマ社製、試薬
特級、5mg/ml)2mlと、フォスファチジルコリ
ン(ナカライテスク社製、試薬特級)をエタノール(ナ
カライテスク社製、試薬特級、99%)に溶解して10
mg/mlとしたもの10mlと、コレステロール(ナ
カライテスク社製、試薬特級)を同じく10mg/ml
のエタノール溶液にしたもの3mlとを合わせ、よく混
合し、抗原液とした。
(2) Antigen solution 2 ml of an ethanol solution of cardiolipin (manufactured by Sigma, special grade reagent, 5 mg / ml) and phosphatidylcholine (special grade reagent manufactured by Nacalai Tesque, Inc.) were added to ethanol (special grade reagent manufactured by Nacalai Tesque, Inc. , 99%) and 10
10 ml of 10 mg / ml and 10 mg / ml of cholesterol (special grade reagent manufactured by Nacalai Tesque)
3 ml of the ethanol solution prepared in 1 above was mixed well and used as the antigen solution.

【0057】(3) ラテックス希釈用緩衝液 100mM Na2 HPO4 (12水和物)および10
0mM Na2 HPO 4 (2水和物)を混合してpHを
7.40に調整したリン酸緩衝液(以下100mMリン
酸緩衝液と略す)に、グリコシルエチルメタクリレート
のホモポリマー(日本精化社製、平均分子量50万、Gl
ucosylethylmethacryrate :以下pGEMAと略す)を
0.1%(W/V)になるように溶解したものをラテッ
クス希釈用緩衝液とした。
(3) Latex dilution buffer 100 mM Na2HPOFour(12 hydrate) and 10
0 mM Na2HPO Four(Dihydrate) is mixed to adjust the pH
Phosphate buffer adjusted to 7.40 (hereinafter 100 mM phosphorus
Glycosyl ethyl methacrylate in acid buffer)
Homopolymer (manufactured by Nippon Seika Co., average molecular weight 500,000, Gl
ucosylethylmethacryrate: hereinafter abbreviated as pGEMA)
Latte that was dissolved to 0.1% (W / V)
Cux dilution buffer.

【0058】(4) ブロッキング用緩衝液 上記100mMリン酸緩衝液に、アジ化ナトリウム(ナ
カライテスク社製、試薬特級)を1%(W/V)になる
ように溶解したものをブロッキング用緩衝液とした。
(4) Blocking buffer A blocking buffer was prepared by dissolving sodium azide (Nacalai Tesque, Inc., reagent grade) in the above 100 mM phosphate buffer to a concentration of 1% (W / V). And

【0059】(5) ラテックス保存用緩衝液 100mMリン酸緩衝液にウシ血清アルブミン(Miles
社製、Fraction V、試薬特級、以下BSAと略す)を1
%(W/V)、アジ化ナトリウム(ナカライテスク社
製、試薬特級)を0.1%(W/V)、エチレンジアミ
ン四酢酸二ナトリウム二水和物(ナカライテスク社製、
試薬特級)を10mM、塩化コリン(ナカライテスク社
製、試薬特級)を500mMになるようにそれぞれ溶解
したものをラテックス保存用緩衝液とした。
(5) Latex storage buffer 100 mM phosphate buffer was added to bovine serum albumin (Miles
Company, Fraction V, special grade reagent, abbreviated as BSA below) 1
% (W / V), sodium azide (manufactured by Nacalai Tesque, special grade reagent) 0.1% (W / V), ethylenediaminetetraacetic acid disodium dihydrate (manufactured by Nacalai Tesque,
Reagent special grade) was dissolved in 10 mM, and choline chloride (Nacalai Tesque, Inc. special reagent grade) was dissolved to 500 mM to prepare a latex storage buffer solution.

【0060】(6) 検体希釈用緩衝液 100mMリン酸緩衝液にpGEMAを1.0%(W/
V)、BSAを0.25%(W/V)、アジ化ナトリウ
ムを0.1%(W/V)になるようにそれぞれ溶解した
ものを検体希釈用緩衝液とした。
(6) Specimen diluting buffer solution 100 mM phosphate buffer solution was added with 1.0% (W / pGEMA) of pGEMA.
V) and BSA were dissolved in 0.25% (W / V) and sodium azide were dissolved in 0.1% (W / V), respectively, to prepare a sample dilution buffer.

【0061】(7) 梅毒陰性血清 正常家兎より採取された血清であって、RPR−カード
テスト法(化学及び血清療法研究所社製)およびセロデ
ィアTRHAキット(富士レビオ社製)の両方により陰
性と判定されたものを用いた。
(7) Syphilis-negative serum Serum collected from normal rabbits, negative by both the RPR-card test method (Chemical and Serum Therapy Research Institute) and Cerrodia TRHA kit (Fujirebio) What was judged to be used.

【0062】(8) 梅毒陽性血清 実験的に梅毒菌を接種し、梅毒にした家兎より採取され
た血清であって、RPR−カードテスト法(化学及び血
清療法研究所社製)およびセロディアTRHAキット
(富士レビオ社製)の両方により陽性と判定されたもの
を用いた。
(8) Syphilis-Positive Serum Serum collected from rabbits experimentally inoculated with syphilis and syphilis, which has RPR-card test (Chemical and Serum Therapy Research Institute) and Cerrodia TRHA The one determined to be positive by both kits (manufactured by Fujirebio) was used.

【0063】試薬の調製 10%(W/V)ポリスチレンラテックス液0.5ml
をラテックス希釈用緩衝液(0.1%(W/V)pGE
MAを含む)0.5ml(ラテックス粒子1重量部に対
しpGEMA0.01重量部)とよく混合した。得られ
た混合液から0.1mlを正確に8mlのポリカーボネ
ートチューブ中に分注し、長さ1cmのスターラバーと
ともに、マグネチックスターラー上で攪拌させながら、
抗原液0.25mlを添加した。室温で引き続き1時間
攪拌したのち、ブロッキング用緩衝液2.0mlを添加
し、引き続き1.5時間、室温で攪拌した。その後、高
速冷却遠心機(日立HR26型)で、19000×g、
10℃で30分遠心洗浄を行った。得られたラテックス
のペレットにラテックス保存用緩衝液2.0mlを添加
し、よく攪拌した。さらにラテックス保存用緩衝液3.
0mlを添加し、攪拌したのち、高速冷却遠心機で、1
9000×g、10℃で30分遠心洗浄を行った。この
洗浄操作を3回繰り返した。
Preparation of Reagent 0.5 ml of 10% (W / V) polystyrene latex solution
A latex dilution buffer (0.1% (W / V) pGE
0.5 ml (including MA) (0.01 part by weight of pGEMA to 1 part by weight of latex particles) was mixed well. 0.1 ml of the obtained mixed solution was accurately dispensed into a polycarbonate tube of 8 ml, and the mixture was stirred on a magnetic stirrer with a 1 cm long star rubber,
0.25 ml of antigen solution was added. After continuously stirring at room temperature for 1 hour, 2.0 ml of blocking buffer was added, and subsequently stirred at room temperature for 1.5 hours. After that, with a high-speed cooling centrifuge (Hitachi HR26 type), 19000 × g,
Centrifugal washing was performed at 10 ° C. for 30 minutes. 2.0 ml of a buffer solution for latex storage was added to the obtained latex pellets, and they were stirred well. Further, a latex storage buffer solution 3.
Add 0 ml and stir, then in a high speed cooling centrifuge 1
Centrifugal washing was performed at 9000 × g and 10 ° C. for 30 minutes. This washing operation was repeated 3 times.

【0064】最終的に得られたペレットにラテックス保
存用緩衝液2.0mlを添加し、超音波破砕機(アスト
ラソン社製、マイクロチップ、出力目盛3、50%サイ
クル)にて氷浴中、1分間ソニケートし、分散させた。
こののち、さらにラテックス保存用緩衝液6.0mlを
添加し、十分混合させた。こうして、固型分0.125
%(W/V)のラテックス懸濁液を調製し、4℃にて保
存した。
To the finally obtained pellet, 2.0 ml of a buffer solution for latex storage was added, and the mixture was sonicated in an ultrasonic crusher (Astrason, Microchip, output scale 3, 50% cycle) in an ice bath, Sonicate for 1 minute and disperse.
After this, 6.0 ml of a latex storage buffer was further added and mixed well. Thus, the solid content 0.125
% (W / V) latex suspension was prepared and stored at 4 ° C.

【0065】検体の調製 先に用意した家兎の梅毒陽性血清のうちRPR法で8倍
を示したものを、生理食塩水(0.9%NaCl水溶
液)にて、2、4、8、16倍希釈し、4、2、1、
0.5倍を示す陽性検体を調製した。また、陰性検体と
して生理食塩水および正常家兎の梅毒陰性血清をそのま
ま用いた。
Preparation of Specimens Rabbit syphilis-positive sera prepared in the above, which showed 8 times the RPR method, were treated with physiological saline (0.9% NaCl aqueous solution) for 2, 4, 8, 16 Dilute four times, 4, 2, 1,
A positive sample showing 0.5 times was prepared. In addition, physiological saline and syphilis-negative serum from normal rabbits were used as they were as negative samples.

【0066】自動分析装置による検体の測定 以下に、全自動生化学分析装置日立7150形(日立製
作所社製)により、検体中の抗リン脂質検体を測定する
方法を示す。
Measurement of Specimen by Automatic Analyzer The method for measuring an antiphospholipid specimen in a specimen by a fully automatic biochemical analyzer Hitachi Model 7150 (manufactured by Hitachi, Ltd.) is shown below.

【0067】 測定モード;Original Abs パラメータ;検体量 20μl ラテックス試薬量 50μl 検体希釈用緩衝液量 350μl 測定波長 ; 570nm 測定時間;検体分注後、ただちに検体希釈用緩衝液が添
加、混合され、そののち、ラテックス試薬が添加、混合
された。ラテックス試薬の添加後80秒後から320秒
後の吸光度の変化量を求め、これを反応量とした。
Measurement mode; Original Abs parameter; Specimen amount 20 μl Latex reagent amount 50 μl Specimen dilution buffer amount 350 μl Measurement wavelength; 570 nm measurement time; Specimen dilution buffer solution is added and mixed immediately after specimen dispensing, and then The latex reagent was added and mixed. The amount of change in the absorbance from 80 seconds to 320 seconds after the addition of the latex reagent was determined and used as the reaction amount.

【0068】検体;先に用意した梅毒陽性血清の希釈系
列および生理食塩水、梅毒陰性血清を検体としてそれぞ
れn=2で測定を行った。
Specimens: The syphilis-positive serum dilution series prepared above, physiological saline, and syphilis-negative sera were used as the specimens, and measurement was carried out at n = 2.

【0069】実施例6 実施例5において、ラテックス希釈用緩衝液中のpGE
MA濃度を0.2%(W/V)にした以外は実施例5と
同様の操作を行った(すなわち、ラテックス粒子1重量
部に対しpGEMAを0.02重量部添加した)。
Example 6 In Example 5, pGE in the latex dilution buffer was used.
The same operation as in Example 5 was carried out except that the MA concentration was 0.2% (W / V) (that is, 0.02 part by weight of pGEMA was added to 1 part by weight of latex particles).

【0070】実施例7 実施例5において、ラテックス希釈用緩衝液中のpGE
MA濃度を0.5%(W/V)にした以外は実施例5と
同様の操作を行った(すなわち、ラテックス粒子1重量
部に対しpGEMAを0.05重量部添加した)。
Example 7 In Example 5, pGE in latex dilution buffer
The same operation as in Example 5 was carried out except that the MA concentration was changed to 0.5% (W / V) (that is, 0.05 part by weight of pGEMA was added to 1 part by weight of latex particles).

【0071】比較例4 実施例5において、ラテックス希釈用緩衝液として、p
GEMAの代わりにBSAを1%(W/V)になるよう
に添加した緩衝液を用いた以外は実施例5と同様の操作
を行った(すなわち、ラテックス粒子1重量部に対しB
SAを0.1重量部添加した)。
Comparative Example 4 In Example 5, p was used as the latex dilution buffer.
The same operation as in Example 5 was carried out except that a buffer solution containing BSA at 1% (W / V) was used in place of GEMA (that is, 1 part by weight of the latex particles was mixed with B.
0.1 part by weight of SA was added).

【0072】比較例5 実施例5において、ラテックス希釈用緩衝液中のpGE
MA濃度を0.01%(W/V)にした以外は実施例5
と同様の操作を行った(すなわち、ラテックス粒子1重
量部に対しpGEMAを0.001重量部添加した)。
Comparative Example 5 In Example 5, pGE in a buffer for diluting latex was used.
Example 5 except that the MA concentration was 0.01% (W / V)
The same operation was performed (that is, 0.001 part by weight of pGEMA was added to 1 part by weight of latex particles).

【0073】比較例6 実施例5において、ラテックス希釈用緩衝液中のpGE
MA濃度を2.0%(W/V)にした以外は実施例5と
同様の操作を行った(すなわち、ラテックス粒子1重量
部に対しpGEMAを0.2重量部添加した)。
Comparative Example 6 In Example 5, pGE in a latex dilution buffer was used.
The same operation as in Example 5 was performed except that the MA concentration was 2.0% (W / V) (that is, 0.2 part by weight of pGEMA was added to 1 part by weight of latex particles).

【0074】測定結果 実施例5〜7で得られた、各検体の吸収光度変化量を表
3に、および比較例4〜6で得られた、各検体の吸収光
度変化量を表4にそれぞれ示す(いずれもn=2の平均
値)。
Measurement Results The amount of change in absorbed light intensity of each sample obtained in Examples 5 to 7 is shown in Table 3, and the amount of change in absorbed light intensity of each sample obtained in Comparative Examples 4 to 6 is shown in Table 4. Shown (all are average values of n = 2).

【0075】[0075]

【表3】 [Table 3]

【表4】 これらの表から明らかなように、実施例の試薬は比較例
のものと比較して、陽性血清では高感度を示し、陰性血
清では非特異反応が全く見られないことがわかる。
[Table 4] As is clear from these tables, the reagents of Examples show higher sensitivity in positive sera and no non-specific reaction in negative sera, as compared with those in Comparative Examples.

【0076】[0076]

【発明の効果】本発明によれば、糖鎖を有する水溶性高
分子を水不溶性担体に導入することにより、水不溶性担
体の疎水性を局所的に高め、抗原または抗体の疎水性相
互作用による吸着量を増大させ、同時に水不溶性担体に
親水性を付与することができる。これにより、自然凝集
あるいは非特異凝集を発生する恐れがなく、長時間保存
しうる、高感度を示す、免疫測定用試薬を提供すること
ができる。
INDUSTRIAL APPLICABILITY According to the present invention, by introducing a water-soluble polymer having a sugar chain into a water-insoluble carrier, the hydrophobicity of the water-insoluble carrier is locally enhanced, and the hydrophobic interaction of the antigen or antibody is caused. It is possible to increase the amount of adsorption and at the same time impart hydrophilicity to the water-insoluble carrier. As a result, it is possible to provide a reagent for immunoassay which has high sensitivity and can be stored for a long time without the risk of spontaneous aggregation or non-specific aggregation.

Claims (3)

【特許請求の範囲】[Claims] 【請求項1】 抗体または抗原を担持した水不溶性担体
に、側鎖に糖類を有する水溶性高分子が導入されてなる
免疫測定用試薬。
1. An immunoassay reagent comprising a water-insoluble carrier carrying an antibody or an antigen, and a water-soluble polymer having a side chain having a saccharide introduced therein.
【請求項2】 水不溶性担体に抗体または抗原を担持し
た後、同担体および抗体または抗原を含む水性液に、側
鎖に糖類を有する水溶性高分子を担体1重量部に対し
0.01〜4重量部になるような濃度で含む水性液を添
加することを特徴とする免疫測定用試薬の製造方法。
2. A water-insoluble carrier is loaded with an antibody or an antigen, and then an aqueous solution containing the carrier and the antibody or the antigen is added with a water-soluble polymer having a saccharide in a side chain in an amount of 0.01 to 1 part by weight of the carrier. A method for producing an immunoassay reagent, which comprises adding an aqueous solution containing a concentration of 4 parts by weight.
【請求項3】 水不溶性担体に抗体または抗原を担持さ
せる際に、担持前または担持と同時に、担体を含む水性
液に、側鎖に糖類を有する水溶性高分子を担体1重量部
に対し0.005〜0.15重量部になるような濃度で
含む水性液を添加することを特徴とする免疫測定用試薬
の製造方法。
3. When supporting an antibody or an antigen on a water-insoluble carrier, before or at the same time as carrying, the water-soluble polymer having a saccharide in a side chain is added to an aqueous liquid containing the carrier in an amount of 0 per 1 part by weight of the carrier. A method for producing an immunoassay reagent, which comprises adding an aqueous solution containing such a concentration as to give 0.005 to 0.15 parts by weight.
JP06127694A 1994-03-30 1994-03-30 Immunoassay reagent and method for producing the same Expired - Lifetime JP3444649B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP06127694A JP3444649B2 (en) 1994-03-30 1994-03-30 Immunoassay reagent and method for producing the same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP06127694A JP3444649B2 (en) 1994-03-30 1994-03-30 Immunoassay reagent and method for producing the same

Publications (2)

Publication Number Publication Date
JPH07270417A true JPH07270417A (en) 1995-10-20
JP3444649B2 JP3444649B2 (en) 2003-09-08

Family

ID=13166531

Family Applications (1)

Application Number Title Priority Date Filing Date
JP06127694A Expired - Lifetime JP3444649B2 (en) 1994-03-30 1994-03-30 Immunoassay reagent and method for producing the same

Country Status (1)

Country Link
JP (1) JP3444649B2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007055283A1 (en) * 2005-11-10 2007-05-18 Jsr Corporation Method for proteomics analysis of nuclear receptor protein complex

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007055283A1 (en) * 2005-11-10 2007-05-18 Jsr Corporation Method for proteomics analysis of nuclear receptor protein complex
JPWO2007055283A1 (en) * 2005-11-10 2009-04-30 Jsr株式会社 Proteomic analysis of nuclear receptor protein complex

Also Published As

Publication number Publication date
JP3444649B2 (en) 2003-09-08

Similar Documents

Publication Publication Date Title
JP3257795B2 (en) Unit-of-use reagent composition for specific binding assays
US4636479A (en) Enhanced agglutination method and kit
US4273867A (en) Method and reagent for counteracting lipemic interference
JPS6071957A (en) Method of promoting immune reaction by ultrasonic treatment
CN108362895B (en) Folic acid detection kit and preparation method thereof
EP0070527B1 (en) Method of assaying biologically active substances and labelling agents therefor
EP0323692A2 (en) Water-insoluble reagent, elements containing same and methods of use
JP3290660B2 (en) Unit-of-use reagent composition for specific binding assay
JP5786188B2 (en) Reagent for measuring C-reactive protein in sample, measuring method, and method for expanding measuring range
EP0243471A1 (en) Solid-phase liposome immunoassay system
JPS5838862A (en) Method of examining auto-blocking antibody and reagent kit used for said method
JP3444649B2 (en) Immunoassay reagent and method for producing the same
JP3786543B2 (en) Immunological reagent
JP2004144687A (en) Method for measuring substance
JP2003344410A (en) Immuno-measurement reagent and immuno-measurement method
JPH09304386A (en) Manufacture of immunity diagnostic drug and immunity diagnostic drug obtained
JP3439542B2 (en) Method for producing reagent for measuring antiphospholipid antibody
JP3396231B2 (en) Immune reaction measurement reagent and immunoreactivity measurement method
JP3328058B2 (en) Method for producing immunodiagnostic drug
JP3359415B2 (en) Method for producing immunodiagnostic agent for measuring antiphospholipid antibody
JP3487651B2 (en) Method for producing immunodiagnostic reagent
JPH11258236A (en) Reagent for measuring anti phospholipid antibody
JP3938627B2 (en) Method for measuring lysine affinity substance
JPS61296270A (en) Reagent for immunological reaction
JPH07113641B2 (en) Method for manufacturing syphilis diagnostic reagent

Legal Events

Date Code Title Description
FPAY Renewal fee payment (prs date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090627

Year of fee payment: 6

FPAY Renewal fee payment (prs date is renewal date of database)

Year of fee payment: 7

Free format text: PAYMENT UNTIL: 20100627

FPAY Renewal fee payment (prs date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100627

Year of fee payment: 7

FPAY Renewal fee payment (prs date is renewal date of database)

Year of fee payment: 8

Free format text: PAYMENT UNTIL: 20110627

FPAY Renewal fee payment (prs date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110627

Year of fee payment: 8

FPAY Renewal fee payment (prs date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120627

Year of fee payment: 9

FPAY Renewal fee payment (prs date is renewal date of database)

Year of fee payment: 9

Free format text: PAYMENT UNTIL: 20120627

FPAY Renewal fee payment (prs date is renewal date of database)

Year of fee payment: 10

Free format text: PAYMENT UNTIL: 20130627

EXPY Cancellation because of completion of term